Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety and Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin and Sulfonylurea or Metformin in T2 Diabetic Patients
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2015
At a glance
- Drugs BGP 15 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors N-Gene Research Laboratories
- 10 Jun 2017 Biomarkers information updated
- 31 Jul 2013 Planned end date changed from 1 Nov 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 10 Jul 2013 This trial has been discontinued in Hungary and has an unknown status in Germany and the USA because this information has not been verified recently in the ClinicalTrials.gov record (last verified June 2011).